EMA和EGP-2在乳腺癌组织中的表达及临床意义

目的通过检测上皮膜抗原（EMA）、表皮糖蛋白基因（EGP-2）在乳腺癌组织中的表达，分析它们与乳腺癌临床病理指标的关系，并研究两者表达的相关性。方法采用免疫组化SP法检测69例乳腺癌及28例乳腺增生组织中EMA和EGP-2的表达水平。结果EMA和EGP-2在癌组织中的表达水平明显高于增生组织，在癌组织中阳性表达率分别为88．41％和91．30％，而在增生组织中则分别为21．43％和25．00％，差别有统计学意义；两种指标的强阳性表达率与肿瘤TNM分期明显相关，TⅢ＋Ⅳ组明显高于TⅠ＋Ⅱ组；在癌组织中EMA和EGP-2的表达呈明显正相关（r=0．374，P〈0．01）。结论EMA和EGP-2的高表达对于乳腺癌的诊断具有重要意义，临床检测两者有助于乳腺癌的预后判断及治疗。

Clinical significance of expression of EMA and EGP-2 in breast carcinoma tissues

Objective To investigate the expression of EMA and EGP - 2 in breast carcinoma tissues, to analyze their relationship with clinical indexes and to observe the correlation with their expression. Methods Immunohistochemical technique was applied to detect the expression levels of EMA and EGP - 2 in tissues of 69 patients with breast carcinoma and 28 patients with breast hyperplasia. Results Expression levels of EMA and EGP - 2 in breast cancer tissues were much higher than those in hyperplasia tissues, and their positive rates were 88.41% and 91.30% respectively. However, they were 21.43% and 25.00% respectively in hyperplasia tissues. Their difference was statistically significant. The strong positive expression rates of two indexes had close relationship with tumor stages, they were much higher in groups of T Ⅲ ＋ Ⅳ than those of T Ⅰ＋ Ⅱ. In breast carcinoma tissues, the expression of EMA was positively related to EGP - 2 （ r = 0. 374, P 〈 0.01 ）. Conclusion The results suggest that the high expression of EMA and EGP - 2 in breast cancer may be important in diagnosis of breast carcinoma. It is helpful to detect these two indexes in prognostic evaluation and treatment of breast carcinoma.